Table 2.
Cancer‐specific genetic risk score in cases and controls
| Cancer type | SNPs (N) | Mean of GRS (95% CI) | P | |
|---|---|---|---|---|
| Cases | Controls | |||
| Bladder | 10 | 1.04 (1‐1.08) | 0.98 (0.97‐0.98) | 3.77E‐03 |
| Breast | 66 | 1.15 (1.11‐1.2) | 1.01 (1‐1.03) | 1.48E‐14 |
| Colorectal | 30 | 1.08 (1.04‐1.12) | 1 (0.99‐1.01) | 8.29E‐06 |
| Glioma | 19 | 1.22 (1.18‐1.26) | 0.98 (0.97‐0.99) | 1.39E‐37 |
| Lung | 6 | 1.01 (0.99‐1.02) | 0.99 (0.98‐0.99) | 1.16E‐02 |
| Melanoma | 17 | 1.2 (1.14‐1.26) | 1.02 (1.01‐1.03) | 5.99E‐11 |
| Ovarian | 11 | 1.12 (1.08‐1.16) | 1.02 (1.01‐1.03) | 1.45E‐04 |
| Pancreatic | 9 | 1.13 (1.07‐1.18) | 1.02 (1.02‐1.03) | 1.45E‐04 |
| Prostate | 79 | 1.3 (1.21‐1.38) | 0.99 (0.98‐1.01) | 2.07E‐18 |
| Renal | 10 | 1.09 (1.06‐1.12) | 1.01 (1‐1.01) | 8.66E‐10 |
| Thyroid | 6 | 1.09 (1.04‐1.15) | 0.98 (0.98‐0.99) | 3.64E‐05 |
CI, confidence interval; GRS, genetic risk score.